Balance Sheet (Annual)

ASX:RMD / RESMED INC Balance Sheet shows account balances for the company at points in time. Balance Sheet data includes Assets, Current Assets, Fixed Assets, Property, Plant and Equipment (PPE), Inventory, Intangibles, Liabilities, Current Liabilities, Debt, Capital Lease Obligations, Common Stock, Retained Earnings, Treasury Stock, and Shareholders Equity.

All numbers are times 1,000 except per share units.

2012 2013 2014 2015 2016 2017
Assets
  Assets Current
    Cash And Cash Equivalents At Carrying Value 809,541 876,048 905,730 717,249 731,434 821,935
    Accounts Receivable Net Current - - 359,593 362,568 382,086 450,530
    Inventory Net 174,351 145,847 165,418 246,859 224,456 268,319
    Prepaid Expense And Other Assets Current - - 78,707 81,168 81,743 103,219
    Assets Current 1,361,151 1,448,849 1,556,209 1,444,182 1,419,719 1,644,003
  Assets Noncurrent
    Property Plant And Equipment Net 434,363 411,433 434,277 387,758 384,276 394,241
    Goodwill 256,209 274,829 289,312 264,261 1,059,245 1,064,874
    Finite Lived Intangible Assets Net 54,827 49,639 45,198 47,142 299,808 261,800
    Deferred Tax Assets Net Noncurrent 23,500 20,053 18,755 12,528 55,496 61,503
    Other Assets Noncurrent 7,819 5,918 17,211 28,389 40,391 42,066
    Assets Noncurrent 776,718 761,872 804,753 740,078 1,839,216 1,824,484
  Assets 2,137,869 2,210,721 2,360,962 2,184,260 3,258,935 3,468,487
Liabilities And Stockholders Equity
  Liabilities Current
    Accounts Payable Current 55,006 60,688 85,405 81,112 92,571 92,763
    Accrued Liabilities Current 127,381 137,674 130,656 132,976 156,805 186,295
    Deferred Revenue Current 41,563 44,953 42,370 36,097 50,009 51,918
    Accrued Income Taxes Current 27,777 30,090 10,392 16,278 39,166 29,150
    Liabilities Current 252,852 574,049 269,558 267,259 638,551 360,126
  Liabilities Noncurrent
    Deferred Revenue Noncurrent 14,384 11,928 16,352 19,284 40,281 53,235
    Deferred Tax Liabilities Noncurrent 8,843 9,895 10,716 8,062 9,061 13,822
    Other Liabilities Noncurrent - - - - 1,211 2,427
    Long Term Debt 250,835 300,786 300,788 300,594 - -
    Accrued Income Taxes Noncurrent 3,380 3,564 5,318 1,754 - -
    Liabilities Noncurrent 277,390 26,156 333,156 329,694 925,553 1,148,095
  Liabilities 530,242 600,205 602,714 596,953 1,564,104 1,508,221
  Commitments And Contingencies - - - - - -
  Stockholders Equity
    Preferred Stock Value 0 - - - - -
    Common Stock Value Outstanding 568 568 561 562 563 569
    Additional Paid In Capital Common Stock 899,717 1,025,064 1,117,644 1,228,795 1,303,238 1,379,130
    Retained Earnings Accumulated Deficit 1,366,712 1,576,641 1,780,396 1,976,020 2,160,299 2,316,237
    Treasury Stock Value 895,826 1,083,845 1,291,910 1,444,554 1,546,611 1,546,611
    Accumulated Other Comprehensive Income Loss Net Of Tax 236,456 92,088 151,557 -173,516 -222,658 -189,059
    Stockholders Equity - - 1,758,248 1,587,307 1,694,831 1,960,266
  Liabilities And Stockholders Equity 2,137,869 2,210,721 2,360,962 2,184,260 3,258,935 3,468,487

Peers - Surgical and Medical Instruments and Apparatus (3841)

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

12h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

13h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...